Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 12,500 shares at $20.00 ($250K) on 2026-06-30, disclosed to the SEC on 2026-07-01.
Chairman and CEO Ron Bentsur purchased 12,500 shares for $250,000, marking the largest insider purchase in the company's history. This move is notable as the stock dropped 25% after pricing a $100 million discounted offering at $20 per share on the same day.
The stock is currently trading at $9.03, up 23.53% over the last year but still 8.6% below its 52-week high of $9.88.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |
| NVCT | BUY | 2024-05-13 | $13K | — | Filing → |